Leerink Partnrs Predicts NeuroPace FY2029 Earnings

NeuroPace, Inc. (NASDAQ:NPCE) – Equities research analysts at Leerink Partnrs issued their FY2029 earnings per share estimates for NeuroPace in a research report issued on Tuesday, January 28th. Leerink Partnrs analyst M. Kratky expects that the company will post earnings per share of $0.43 for the year. The consensus estimate for NeuroPace’s current full-year earnings is ($1.00) per share.

NeuroPace (NASDAQ:NPCE) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.07. The firm had revenue of $21.06 million during the quarter, compared to the consensus estimate of $19.33 million. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%. During the same quarter in the prior year, the company earned ($0.28) EPS.

A number of other research firms also recently weighed in on NPCE. Wells Fargo & Company increased their target price on shares of NeuroPace from $13.00 to $17.00 and gave the company an “overweight” rating in a research report on Thursday. UBS Group began coverage on NeuroPace in a report on Tuesday, January 21st. They set a “buy” rating and a $17.00 price objective for the company. Finally, JPMorgan Chase & Co. boosted their target price on NeuroPace from $9.00 to $14.00 and gave the company an “overweight” rating in a research note on Tuesday, December 17th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $14.80.

NeuroPace Stock Performance

NASDAQ NPCE opened at $14.19 on Thursday. The company has a market capitalization of $423.57 million, a PE ratio of -14.19 and a beta of 2.02. The company has a debt-to-equity ratio of 6.03, a quick ratio of 4.77 and a current ratio of 5.59. NeuroPace has a 52-week low of $5.45 and a 52-week high of $18.15. The company has a 50-day simple moving average of $11.75 and a 200 day simple moving average of $8.81.

Insider Transactions at NeuroPace

In related news, insider Martha Morrell sold 3,200 shares of the firm’s stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $15.01, for a total value of $48,032.00. Following the sale, the insider now directly owns 87,062 shares of the company’s stock, valued at $1,306,800.62. This trade represents a 3.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 22.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. KCK LTD. purchased a new position in shares of NeuroPace in the 4th quarter worth about $58,981,000. Millennium Management LLC raised its stake in shares of NeuroPace by 13.3% during the second quarter. Millennium Management LLC now owns 686,037 shares of the company’s stock worth $5,186,000 after acquiring an additional 80,324 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of NeuroPace by 8.7% in the 3rd quarter. Geode Capital Management LLC now owns 317,192 shares of the company’s stock worth $2,211,000 after acquiring an additional 25,330 shares during the last quarter. Barclays PLC boosted its stake in shares of NeuroPace by 346.0% in the 3rd quarter. Barclays PLC now owns 20,633 shares of the company’s stock valued at $144,000 after purchasing an additional 16,007 shares in the last quarter. Finally, State Street Corp grew its holdings in shares of NeuroPace by 9.1% during the 3rd quarter. State Street Corp now owns 155,490 shares of the company’s stock valued at $1,084,000 after purchasing an additional 12,912 shares during the last quarter. Institutional investors own 78.83% of the company’s stock.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.